This is an Open Access article licensed under the terms of the Creative Commons AttributionNonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Distribution permitted for non-commercial purposes only. Abstract Objectives: We investigated the role of miR-205 in the osteogenic differentiation of vascular smooth muscle cells (VSMCs). Methods: Osteogenic differentiation of human aortic smooth muscle cells (HASMCs) was induced by 10 mM β-glycerophosphate (β-GP). Alizarin Red S staining, alkaline phosphatase (ALP) activity and osteocalcin secretion were used to determine osteogenic differentiation of HASMCs. Quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) was used to measure the expression of miR-205 in HASMCs. Results: The expression of endogenous miR-205 was decreased in HASMCs during β-glycerophosphateinduced calcification. Overexpression of miR-205 inhibited the differentiation of HASMCs into osteoblast-like cells, as evidenced by a decrease in ALP activity, osteocalcin secretion, and Runx2 expression, whereas miR-205 depletion enhanced osteoblastic differentiation of HASMCs. Runx2 and Smad1 were identified as direct targets of miR-205 by computational analysis and experimental assays. Conclusion: The present study shows that miR-205 may negatively regulate the β-glycerophosphate-induced calcification of HASMCs, at least partially by targeting Runx2 and Smad1.
Introduction
Vascular calcification is the deposition of calcium phosphate crystals in cardiovascular tissues [1] . It reduces vessel elasticity, resulting in impaired cardiovascular hemodynamics and increased morbidity and mortality associated with hypertension, aortic stenosis, cardiac hypertrophy, and other cardiovascular diseases [2] . In the past, vascular calcification was considered a passive and degenerative process; however, recent research has shown that this process is regulated by a mechanism similar to that of bone formation [3] . The identification of bone calcification regulatory factors in blood vessels and the differential expression of these factors in nondiseased and diseased vessels verified that vascular calcification is a regulated process analogous to skeletal bone formation but orchestrated by vascular smooth muscle cells (VSMCs) [4] [5] [6] . VSMCs release matrix vesicles with the capacity to concentrate calcium and phosphate, acting as nidus for mineralization, and undergo a phenotypic transition in which the expression of transcription factors associated with differentiated chondrocytes and osteoblasts induce the expression of mineralization regulating proteins such as alkaline phosphatase, osteopontin and osteocalcin [7] .
MicroRNAs (miRNAs) are a class of small (16−25 nucleotides), single-stranded noncoding RNAs that negatively regulate gene expression through incomplete base-pairing to the 3′ untranslated region (3′-UTR) of target mRNAs, inducing mRNA degradation or blocking translation [8, 9] . miRNAs have been studied extensively because of their roles as regulators of cell differentiation, growth, proliferation and apoptosis, and therefore their involvement in several diseases, in particular their role in cancer [10] . Importantly, miRNAs are highly expressed in the cardiovascular system and their involvement not only in cardiovascular development, but also in cardiovascular diseases including atherosclerosis and pulmonary arterial hypertension has only recently began to be understood [11, 12] . Several miRNAs, such as miR-125b, miR-204, miR-29a/b, miR-30b/c and miR-133a, have been identified that are involved in VSMC calcification [13] [14] [15] [16] [17] . However, the mechanisms underlying the effect of miRNAs and their targets in the modulation of VSMC differentiation leading to vascular calcification remain to be elucidated.
MiR-205 was previously shown to be among a series of miRNAs that regulate osteoblast differentiation and bone formation by directly targeting Runx2 [18, 19] . Whether miR-205 is also involved in VSMC osteogenic differentiation has not yet been explored. In this study, we found that miR-205 is a negative regulator of osteogenic differentiation in VSMCs, and identified Runx2 and Smad1 as its direct targets.
Materials and Methods

Cell culture
Human aortic smooth muscle cells (HASMCs) were purchased from Promocell (Heidelberg, Germany) and cultured in DMEM supplemented with 10% fetal bovine serum (FBS) and 100 units/ml penicillin/ streptomycin at 37°C and 5% CO 2 . To induce calcification, the cells were incubated in DMEM containing 15% FBS supplemented with 10 mM β-glycerophosphate (β-GP).
Measurements of ALP activity and osteocalcin secretion
To determine the activity of alkaline phosphatase (ALP), cells were washed with PBS and scraped into a solution containing 20 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1% Triton X-100, 0.02% NaN 3 , and 1 μg/mL aprotinin. Lysates were homogenized and assayed for ALP activity by measuring the release of p-nitrophenol at 37°C using a spectrophotometer. Results were normalized to total cellular protein content. Osteocalcin secretion into the culture media was measured by using a specific radioimmunoassay kit (DiaSorin Corp., Stillwater, MN, USA) according to the manufacturer's instructions. Protein expression was normalized to total cellular protein measured by the Bradford protein assay. 
Alizarin Red S staining
The formation of a mineralized matrix was determined by Alizarin Red S staining. HASMCs cultured in DMEM supplemented with 10 mM β-GP were fixed in 70% ethanol for 1 h at room temperature and stained with 40 mM Alizarin Red S for 10 min. Then, cells were washed with PBS to eliminate nonspecific staining and the stained matrix was photographed using a digital microscope. For quantification of staining, the Alizarin Red S stain was released from the cell matrix by incubation in cetyl-pyridinium chloride for 15 min and the amount of released dye was measured by spectrophotometry at 540 nm. The results were normalized to total cellular protein content.
Quantitative reverse transcriptase PCR (qRT-PCR)
qRT-PCR was performed as described previously [20] . Briefly, total RNA was isolated using TRIzol reagent (Invitrogen). For quantification of miR-205, reverse transcription and qPCR were performed using the TaqMan MicroRNA Reverse Transcription Kit and TaqMan miRNA assay (Applied Biosystems, Foster City, CA, USA). qRT-PCR analyses for RUNX2 and Smad1 mRNAs were performed by using with SuperScript II (Invitrogen) and SYBR Green PCR Maser Mix (Applied Biosystems). Experiments were performed in triplicate. Relative expression of miRNA or mRNA was normalized to the expression of U6 or β-actin and evaluated by the 2 −ΔΔCt method.
Western blotting
Cells were harvested and lysed in RIPA buffer with protease and phosphatase inhibitors (Roche, Indianapolis, IN, USA). The protein concentration was assayed by BCA (Bio-Rad). Approximately 20 to 50 μg of total protein was separated by 10% SDS-PAGE and transferred to polyvinylidene difluoride membranes. Membranes were blocked in tris-buffered saline containing 0.05% Tween 20 and 5% skim milk and then probed with antibodies against Runx2, Smad1 and β-actin (Santa Cruz Biotechnology, Santa Cruz, California, USA). Membranes were then washed and incubated with the appropriate secondary antibodies and detected using enhanced chemiluminescence. Band intensity was quantified by using ImageJ software.
Plasmid construction
The full-length open reading frame of Runx2 or Smad1 was cloned into pcDNA3.1 (+) to generate their expression vectors. The wild-type Runx2 or Smad1 3′-UTR (WT) was cloned into the pGL3-basic vector (Promega, Madison, WI, USA). Site-directed mutagenesis of the miR-205 seed sequence in the 3′-UTR (Mut) was performed using the QuikChange™ Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA).
Oligonucleotide transfection
Cells were seeded into 6-well plates, transfected with miR-205 mimics, anti-miR-205, Runx2 siRNA, Smad1 siRNA or the respective controls (GenePharma, Shanghai, China) using Lipofactamine™ RNAiMAX (Invitrogen), or transfected with plasmids using Lipofactamine 2000 reagent (Invitrogen). The cells were collected for assays 48 h after transfection.
Luciferase assays
For luciferase assays, HASMCs were cultured in 24-well plates and co-transfected with luciferase reporter plasmid and miR-205 mimics and pRL-TK vector (Promega) using Lipofectamine 2000 (Invitrogen). Cells were harvested and lysed 48 h after transfection, and luciferase activity was measured using the Dual-Luciferase Reporter Assay System (Promega). Renilla-luciferase was used for normalization. The experiments were performed independently in triplicate.
Results
miR-205 levels are reduced in HASMCs undergoing osteoblastic differentiation
To induce the calcification of HASMCs, cells were incubated in DMEM supplemented with 10 mM β-GP. As shown in Fig. 1A-D , increased matrix mineralization, Runx2 expression, ALP activity and osteocalcin levels were induced when cells were cultured under calcification conditions. To examine the possible association between miR-205 and HASMC calcification, the expression levels of miR-205 were determined by qRT-PCR, which showed a statistically significant downregulation of the expression of miR-205 in response to β-GP treatment (Fig.  1E) , indicating that miR-205 is downregulated during the calcification of HASMCs.
miR-205 inhibits β-GP-induced osteoblastic differentiation of HASMCs
To further investigate the role of miR-205 in the osteoblastic differentiation of HASMCs, cells were transfected with miR-205 mimics or anti-miR-205 or the respective controls, and the levels of miR-205 were determined by qRT-PCR. miR-205 up-and down-regulation could be maintained for approximately 8 days in these cells (Fig. 2A) . miR-205 silencing significantly enhanced osteoblastic differentiation, which was indicated by enhanced in vitro matrix mineralization, up-regulated Runx2 protein expression, increased ALP activity and osteocalcin secretion in anti-miR-205-transfected HASMCs compared with cells transfected with miR-ctrl ( Fig. 2B-E) . In contrast, matrix mineralization, Runx2 protein expression, ALP activity and osteocalcin secretion were reduced in miR-205 minics-treated HASMCs (Fig.  2B-E) . Together, these results indicate that miR-205 plays a negative role in the regulation of osteoblastic differentiation of HASMCs.
Smad1 and Runx2 are common targets of miR-205
Given that Runx2 and Smad1, which are key downstream mediators of bone morphogenetic protein-2 signaling [21] , have been previously reported to be target genes of showed that overexpression of miR-205 significantly decreased the luciferase activity of the wt-3′-UTRs of Runx2 and Smad1 compared to miR-control transfected cells whereas it had no effect on the mut-3′-UTRs (Fig. 3B) , indicating that miR-205 suppressed the expression of Runx2 and Smad1 by directly binding to target sites in their 3′-UTRs. Furthermore, qRT-PCR analysis showed that miR-205 overexpression had no significant effect on Runx2 and Smad1 mRNA levels (Fig. 3C) . However, miR-205 overexpression significantly downregulated the expression of the Runx2 and Smad1 proteins compared to untransfected controls or miRcontrol transfected cells (Fig. 3D) . These results support the bioinformatics predictions indicating Runx2 and Smad1 3′-UTRs as direct targets of miR-205. of cardiovascular disease and mortality [25] , and calcification of the abdominal aorta is an important predictor of subsequent cardiovascular events [26] . Therefore, elucidation of the mechanisms underlying the process of vascular calcification and identification of the factors involved is important. In the present study, we showed that miR-205 negatively regulates the conversion of VSMCs into bone-like cells and identified Runx2 and Smad1 as direct targets of miR-205, whose miR-205 induced downregulation mediates its effect on osteogenic differentiation. Although several miRNAs that are expressed in VSMCs have been identified [13] [14] [15] [16] [17] , investigation of their roles in vascular calcification is limited. Recently, miR-205 was identified as a miRNA targeting the osteogenic regulator Runx2 in mesenchymal cell types [18, 19] . However, it is unknown if miR-205 exerts any effect on calcification of VSMCs. In the present study, we found that miR-205 was downregulated during HASMC calcification and inhibits the β-GP-induced osteoblastic differentiation of HASMCs. Gain of function studies showed that overexpression of miR-205 decreased ALP activity, osteocalcin secretion and the expression of Runx2, whereas inhibition of miR-205 expression had the opposite effects. This inverse correlation between miR-205 expression and the activity and levels of important markers of osteoblast differentiation demonstrated the role of miR-205 as a negative regulator of osteogenic differentiation.
To further investigate the molecular mechanism by which miR-205 inhibits osteogenic differentiation, we conducted computational search for the target genes of miR-205 and found that Smad1 was a possible target in addition of Runx2, because complementary sequence of miR-205 is identified in the 3′-UTR of their mRNAs. Our results showed that miR-205 overexpression downregulated Runx2 and Smad1 protein, and luciferase activity assays confirmed the direct interaction between miR-205 and the 3′-UTRs of Runx2 and Smad1. 
Cellular Physiology and Biochemistry
Runx2 is an essential transcription factor for osteoblast differentiation. It also plays important roles in the osteogenic transdifferentiation as well as in the calcification of VSMCs [14] . Smad1 is phosphorylated in response to the binding of bone morphogenetic protein (BMP) to BMP receptors on the cell surface and forms a complex with other Smad proteins that is translocated to the nucleus, where it regulates the transcription of BMP target genes [27] . BMP-Smad signaling controls osteoblast differentiation and bone formation. Furthermore, BMP activated Smads interact with Runx2 to enhance the transcription of osteoblast-specific genes [28] , and the interaction of Smad1 with Runx2 on the promoter of target genes controls osteoblast gene expression and differentiation [29] . The regulation of Runx2 and Smad1 by different miRNAs in relation to osteogenic differentiation has been shown in previous studies [14, 16, 17, 30, 31] . In the present study, we found that overexpression of Runx2 or Smad1 reversed the negative effects of miR-205 on ALP activity and osteocalcin secretion, whereas silencing of Runx2 or Smad1 abolished the anti-miR-205-induced increase of ALP activity and osteocalcin secretion. These results confirm that miR-205 inhibits osteogenic differentiation by negatively regulating Runx2 and Smad1.
In summary, the present study showed that miR-205 acts as a negative regulator of osteogenic differentiation of VSMCs at least in part by targeting Runx2 and Smad1 and confirmed the involvement of miRNAs in vascular calcification. Our results indicate that miR-205 could be a useful marker of osteogenic differentiation and the modulation of its expression could be a potential therapeutic strategy for the prevention or treatment of a variety of diseases associated with vascular calcification.
